JP7003045B2 - 神経変性の治療のための方法及び医薬組成物 - Google Patents
神経変性の治療のための方法及び医薬組成物 Download PDFInfo
- Publication number
- JP7003045B2 JP7003045B2 JP2018541671A JP2018541671A JP7003045B2 JP 7003045 B2 JP7003045 B2 JP 7003045B2 JP 2018541671 A JP2018541671 A JP 2018541671A JP 2018541671 A JP2018541671 A JP 2018541671A JP 7003045 B2 JP7003045 B2 JP 7003045B2
- Authority
- JP
- Japan
- Prior art keywords
- dfo
- disease
- complex
- pharmaceutical composition
- metal
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/547—Chelates, e.g. Gd-DOTA or Zinc-amino acid chelates; Chelate-forming compounds, e.g. DOTA or ethylenediamine being covalently linked or complexed to the pharmacologically- or therapeutically-active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/164—Amides, e.g. hydroxamic acids of a carboxylic acid with an aminoalcohol, e.g. ceramides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
- A61K31/315—Zinc compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/242—Gold; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/244—Lanthanides; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
- A61K33/30—Zinc; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Description
本研究では、脳に浸潤するZn-DFO錯体の能力を検討した。ラットに漸増量のDFO単独又はZn-DFO錯体を腹腔内(IP)注射し、DFOの濃度を脳で測定し、これによりそれらの浸潤性を監視した。
本研究では、C57BL/6マウスにおける挫傷脊髄損傷モデルを用いて、金属-DFO錯体の脊髄損傷に対する治療効果を試験した。
本研究では、マウスの実験的自己免疫脳脊髄炎(EAE)を用いて、多発性硬化症(MS)に対する金属-DFO錯体の治療効果を試験する。
本研究では、マウスにおける1-メチル-4-フェニル-1,2,3,6-テトラヒドロピリジン(MPTP)モデルを用いて、パーキンソン病に対する金属-DFO錯体の治療効果を試験する。
本研究では、マウスにおけるストレプトゾトシン(STZ)誘発モデルを用いて、金属-DFO錯体のアルツハイマー病に対する治療効果を試験する。
Banin,E.;Morad,Y.;Berenshtein,E.;Obolenskt,A.;Yahalom,C.;Goldich,J.;Adibelli,F.M.;Zuniga,G.;DeAnda,M.;Pe’er J.;Chevion,M.Injury induced by chemical warfare agents:characterization and treatment of ocular tissues exposed to nitrogen mustard.Invest Ophthalmol Vis Sci.2003,44(7),2966-2972
Basso,D.M.;Fischer,L.C.;Anderson,A.J.;Jakeman,L.B.;McTigue,D.M.;Popovich,P.G.Basso Mouse Scale for locomotion detects differences in recovery after spinal cord injury in five common mouse strains.J Neurotrauma.2006,23(5),635-659
Bibi,H.;Vinokur,V.;Waisman,D.;Elenberg,Y.;Landesberg,A.;Faingersh,A.;Yadid,M.;Brod,V.;Pesin,J.;Berenshtein,E.;Eliashar,R.;Chevion,M.Zn/Ga-DFO iron-chelating complex attenuates the inflammatory process in a mouse model of asthma.Redox Biol.2014,2,814-819
Bittner,S.;Afzali,A.M.;Wiendl,H.;Meuth,S.G.Myelin oligodendrocyte glycoprotein(MOG35-55)induced experimental autoimmune encephalomyelitis(EAE)in C57BL/6 mice.J Vis Exp.2014,86
Chevion,M.A site-specific mechanism for free radical induced biological damage:the essential role of redox-active transition metals.Free Radic Biol Med.1988,5(1),27-37
Chevion,M.Protection against free radical-induced and transition metal-mediated damage:the use of“pull”and“push”mechanisms.Free Radic Res Commun.1991,12-13,691-696
Chevion,M.;Jiang,Y.;Har-El,R.;Berenshtein,E.;Uretzky,G.;Kitrossky,N.Copper and iron are mobilized following myocardial ischemia:possible predictive criteria for tissue injury.Proc Natl Acad Sci USA 1993,90(3),1102-1106
Chevion,M.;Berenshtein,E.;Zhu,B-Z.The role of transition metal ions in free radical-mediated damage.In:Reactive oxygen species in biological systems:an interdisciplinary approach,Colton and Gilbert(Eds.),1998,Plenum Press,New York,pp 103-131
Cohen-Adad,J.;Wheeler-Kingshott,C.Quantitative MRI of the Spinal Cord,Academic Press,2014,p196
Connor,J.R.;Menzies,S.L.;Burdo,J.R.;Boyer,P.J.Iron and iron management proteins in neurobiology.Pediatr Neurol.2001,25(2),118-129
Faden,A.I.;Wu,J.;Stoica B.A.;Loane,D.J.Progressive inflammation-mediated neurodegeneration after traumatic brain or spinal cord injury.Br J Pharmacol.2016 173(4),681-691
Jackson-Lewis,V.;Przedborski,S.Protocol for the MPTP mouse model of Parkinson’s disease.Nat Protoc.2007,2(1),141-151
Kim,N.H.;Park,S.J.;Jin,J.K.;Kwon,M.S.;Choi E.K.;Carp,R.I.;Kim Y.S.Increased ferric iron content and iron-induced oxidative stress in the brains of scrapie-infected mice.Brain Res.2000,884(1-2),98-103
Kumar,V.;Gill,K.D.Aluminium neurotoxicity:neurobehavioural and oxidative aspects.Arch Toxicol.2009,83(11),965-978
Mantyh,P.W.;Ghilardi,J.R.;Rogers,S.;DeMaster,E.;Allen,C.J.;Stimson,E.R.,Maggio,J.E.,Aluminum,iron,and zinc ions promote aggregation of physiological concentrations of beta-amyloid peptide.J Neurochem.1993,61(3),1171-1174
Morad,Y.;Banin,E.;Averbukh,E.;Berenshtein,E.;Obolensky,A.;Chevion,M.Treatment of ocular tissues exposed to nitrogen mustard:beneficial effect of zinc desferrioxamine combined with steroids.Invest Ophthalmol Vis Sci.2005,46(5),1640-1646
Orcutt,K.M.;Jones,W.S.;McDonald,A.;Schrock,D.;Wallace,K.J.A lanthanide-based chemosensor for bioavailable Fe3+ using a fluorescent siderophore:an assay displacement approach.Sensors 2010,10(2),1326-1337
Ravelli,K.G.;Rosario,B.D.;Camarini,R.;Hernandes,M.S.;Britto,L.R.Intracerebroventricular Streptozotocin as a Model of Alzheimer’s Disease:Neurochemical and Behavioral Characterization in Mice.Neurotox Res.2016
Rouault,T.Iron metabolism in the CNS:implications for neurodegenerative diseases.Nature Reviews Neuroscience 2013,14,551-564
Scheiber,I.F.;Mercer,J.F.;Dringen,R.Metabolism and functions of copper in brain.Prog Neurobiol.2014,116,33-57
Siganos,C.S.;Frucht-Pery,J.;Muallem,M.S.;Berenshtein,E.;Naoumidi,I.;Ever-Hadani,P.;Pallikaris I.G.;Siganos D.S.;Chevion,M.Topical use of zinc desferrioxamine for corneal alkali injury in a rabbit model.Cornea 1998,17(2),191-195
Singh,N.;Haldar,S.;Tripathy,A.K.;McElwee,M.K.;Horback,K.;Beserra,A.Iron in neurodegenerative disorders of protein misfolding:a case of prion disorders and Parkinson’s disease.Antioxid Redox Signal 2014 21(3),471-484
Sooriyaarachchi,M.;Gailer,J.Removal of Fe3+ and Zn2+ from plasma metalloproteins by iron chelating therapeutics depicted with SEC-ICP-AES.Dalton Trans.2010,39(32),7466-7473
Wan,W.;Cao,L.;Kalionis,B.;Xia,S.;Tai,X.Applications of Induced Pluripotent Stem Cells in Studying the Neurodegenerative Diseases.Stem Cells Int.2015,2015,382530
Ward,R.E.;Huang,W.;Kostusiak,M.;Pallier,P.N.;Michael-Titus,A.T.;Priestlry,J.V.A characterization of white matter pathology following spinal cord compression injury in the rat.Neuroscience.2014,260,227-239
Williams,T.L.;Urbanc,B.;Marshal,K.E.;Vadukul,D.M.;Jenkins,A.T.;Serpell,L.C.Europium as an inhibitor of Amyloid-β(1-42)induced membrane permeation.FEBS Lett.2015,589(21),3228-3236
Claims (5)
- 神経変性を予防、阻害、軽減又は改善するための医薬組成物であって、
亜鉛-DFO錯体又はガリウム-DFO錯体と、薬学的に許容される担体とを含み、
前記神経変性は、パーキンソン病、アルツハイマー病、筋萎縮性側索硬化症、ハンチントン病及び加齢性脳変性から選択される神経変性疾患、障害又は症状、
機械的な力又は出血によって引き起こされる損傷によって誘発される障害又は症状、
クロイツフェルト・ヤコブ病若しくはそのサブタイプ、ゲルストマン・シュトロイスラー・シャインカー症候群、致死性家族性不眠症、クールー病、家族性海綿状脳症及び多系統萎縮症から選択されるプリオンによって引き起こされる疾患、障害又は症状から選択される、医薬組成物。
む医薬組成物。 - Zn-DFO錯体とGa-DFO錯体との組み合わせを含み、前記組み合わせにおける前記Ga-DFO錯体に対する前記Zn-DFO錯体の量比は、100:1~1:100の範囲である請求項1に記載の医薬組成物。
- 神経変性を予防、阻害、軽減又は改善するための医薬組成物の製造における亜鉛-デスフェリオキサミンB錯体又はガリウム-デスフェリオキサミンB錯体又はその組み合わせの使用であって、
前記神経変性は、パーキンソン病、アルツハイマー病、筋萎縮性側索硬化症、ハンチントン病及び加齢性脳変性から選択される神経変性疾患、障害又は症状、
機械的な力又は出血によって引き起こされる損傷によって誘発される障害又は症状、
クロイツフェルト・ヤコブ病若しくはそのサブタイプ、ゲルストマン・シュトロイスラー・シャインカー症候群、致死性家族性不眠症、クールー病、家族性海綿状脳症及び多系統萎縮症から選択されるプリオンによって引き起こされる疾患、障害又は症状から選択される、使用。 - キットであって、
(i)Zn-デスフェリオキサミンB錯体(DFO)、Ga-デスフェリオキサミンB錯体(DFO)又はそれらの薬学的に許容される塩を含む第1の医薬組成物と、
(ii)少なくとも1つの金属のイオンを含む第2の医薬組成物と、
(iii)前記DFOと前記少なくとも1つの金属との錯体をその場で得て、それにより
パーキンソン病、アルツハイマー病、筋萎縮性側索硬化症、ハンチントン病、加齢性脳変性、
機械的な力又は出血によって引き起こされる損傷によって誘発される障害又は症状、ならびに
クロイツフェルト・ヤコブ病又はそのサブタイプ、ゲルストマン・シュトロイスラー・シャインカー症候群、致死性家族性不眠症、クールー病、家族性海綿状脳症、多系統萎縮症から選択されるプリオンによって引き起こされる疾患、障害又は症状
から選択される神経変性を予防、阻害、軽減又は改善するために、任意の順序で且つ6時間を超えない時間以内に前記組成物を同時又は逐次的のいずれかで投与するための使用説明書とを含むキット。 - 前記第2の医薬組成物は、Zn及びGaの両方のイオンを含み、及び前記Gaイオンに対する前記Znイオンの量比は、100:1~1:100の範囲である請求項4に記載のキット。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662293803P | 2016-02-11 | 2016-02-11 | |
US62/293,803 | 2016-02-11 | ||
PCT/IL2017/050159 WO2017137988A1 (en) | 2016-02-11 | 2017-02-08 | Method and pharmaceutical composition for treatment of neurodegeneration |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2019519465A JP2019519465A (ja) | 2019-07-11 |
JP7003045B2 true JP7003045B2 (ja) | 2022-02-04 |
Family
ID=59563756
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2018541671A Active JP7003045B2 (ja) | 2016-02-11 | 2017-02-08 | 神経変性の治療のための方法及び医薬組成物 |
Country Status (11)
Country | Link |
---|---|
US (1) | US11033630B2 (ja) |
EP (1) | EP3413882A4 (ja) |
JP (1) | JP7003045B2 (ja) |
KR (1) | KR20180105701A (ja) |
CN (1) | CN108601750A (ja) |
AU (1) | AU2017216926A1 (ja) |
CA (1) | CA3012582A1 (ja) |
IL (1) | IL260890A (ja) |
MX (1) | MX2018009662A (ja) |
SG (1) | SG11201806157WA (ja) |
WO (1) | WO2017137988A1 (ja) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20200143716A (ko) * | 2018-04-13 | 2020-12-24 | 모데차이 체비온 | 탈수초 치료용 조성물 및 방법 |
EP3781143A4 (en) * | 2018-04-15 | 2022-01-05 | Mordechai Chevion | COMPOSITIONS AND METHODS FOR THE TREATMENT OF IRON OVERLOAD |
CN111035653B (zh) * | 2019-12-27 | 2023-01-06 | 武汉广行科学研究有限公司 | 用于治疗多发性硬化症的组合物和方法 |
KR102499338B1 (ko) * | 2021-02-03 | 2023-02-10 | 한림대학교 산학협력단 | 알츠하이머병의 예방 또는 치료용 약학 조성물 |
KR102674622B1 (ko) * | 2021-10-15 | 2024-06-11 | 아주대학교산학협력단 | 데페록사민을 포함하는 근감소증의 예방, 개선 또는 치료용 조성물 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004060490A1 (en) | 2003-01-07 | 2004-07-22 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Composition comprising a desferrioxamine-metal complex and its use for treating tissue damage following exposure to warfare agent |
US20060039995A1 (en) | 2004-08-13 | 2006-02-23 | Healthpartners Research Foundation | Methods for providing neuroprotection for the animal central nervous system against the effects of ischemia, neurodegeneration, trauma, and metal poisoning |
JP2009507006A (ja) | 2005-09-02 | 2009-02-19 | ノイラクソ ビオファルマソイティカルス ゲゼルシャフト ミット ベシュレンクテル ハフツング | 鉄キレート剤を含む医薬組成物 |
US20140179789A1 (en) | 2004-08-13 | 2014-06-26 | Healthpartners Research Foundation | Methods of treating huntington's disease comprising administering metal chelators to the upper one-third of the nasal cavity |
Family Cites Families (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4166452A (en) | 1976-05-03 | 1979-09-04 | Generales Constantine D J Jr | Apparatus for testing human responses to stimuli |
US4256108A (en) | 1977-04-07 | 1981-03-17 | Alza Corporation | Microporous-semipermeable laminated osmotic system |
US4265874A (en) | 1980-04-25 | 1981-05-05 | Alza Corporation | Method of delivering drug with aid of effervescent activity generated in environment of use |
MX12394A (es) * | 1987-07-23 | 1993-12-01 | Ciba Geigy Ag | Procedimiento par la obtencion de carbamatos de polietilenglicol. |
IL91047A (en) | 1989-07-19 | 1993-06-10 | Yissum Res Dev Co | Zinc complexes for the treatment of free radical- induced diseases |
US5618838A (en) * | 1993-06-18 | 1997-04-08 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Gallium complexes for the treatment of free radical-induced diseases |
GB0108770D0 (en) * | 2001-04-06 | 2001-05-30 | Eisai London Res Lab Ltd | Inhibitors |
WO2011021203A2 (en) | 2009-08-19 | 2011-02-24 | Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd. | Desferrioxamine-metal complexes for the treatment of immune-related disorders |
-
2017
- 2017-02-08 CN CN201780010897.8A patent/CN108601750A/zh active Pending
- 2017-02-08 SG SG11201806157WA patent/SG11201806157WA/en unknown
- 2017-02-08 MX MX2018009662A patent/MX2018009662A/es unknown
- 2017-02-08 AU AU2017216926A patent/AU2017216926A1/en not_active Abandoned
- 2017-02-08 US US16/074,291 patent/US11033630B2/en active Active
- 2017-02-08 CA CA3012582A patent/CA3012582A1/en not_active Abandoned
- 2017-02-08 WO PCT/IL2017/050159 patent/WO2017137988A1/en active Application Filing
- 2017-02-08 KR KR1020187024799A patent/KR20180105701A/ko unknown
- 2017-02-08 JP JP2018541671A patent/JP7003045B2/ja active Active
- 2017-02-08 EP EP17749978.7A patent/EP3413882A4/en not_active Withdrawn
-
2018
- 2018-07-31 IL IL260890A patent/IL260890A/en unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2004060490A1 (en) | 2003-01-07 | 2004-07-22 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Composition comprising a desferrioxamine-metal complex and its use for treating tissue damage following exposure to warfare agent |
US20060039995A1 (en) | 2004-08-13 | 2006-02-23 | Healthpartners Research Foundation | Methods for providing neuroprotection for the animal central nervous system against the effects of ischemia, neurodegeneration, trauma, and metal poisoning |
US20140179789A1 (en) | 2004-08-13 | 2014-06-26 | Healthpartners Research Foundation | Methods of treating huntington's disease comprising administering metal chelators to the upper one-third of the nasal cavity |
JP2009507006A (ja) | 2005-09-02 | 2009-02-19 | ノイラクソ ビオファルマソイティカルス ゲゼルシャフト ミット ベシュレンクテル ハフツング | 鉄キレート剤を含む医薬組成物 |
Non-Patent Citations (4)
Title |
---|
British Journal of Pharmacology,2005年,146(8),pp.1041-1059 |
IOVS,2005年,46(5),pp.1640-1646 |
Medicinal Research Reviews,2009年,29(4),pp.547-570 |
The Journal of Thoracic and Cardiovascular Surgery,2001年,121(6),pp.1169-1178 |
Also Published As
Publication number | Publication date |
---|---|
EP3413882A4 (en) | 2019-10-09 |
WO2017137988A1 (en) | 2017-08-17 |
US20190358334A1 (en) | 2019-11-28 |
IL260890A (en) | 2018-10-31 |
EP3413882A1 (en) | 2018-12-19 |
US11033630B2 (en) | 2021-06-15 |
JP2019519465A (ja) | 2019-07-11 |
CA3012582A1 (en) | 2017-08-17 |
SG11201806157WA (en) | 2018-08-30 |
MX2018009662A (es) | 2018-09-11 |
KR20180105701A (ko) | 2018-09-28 |
CN108601750A (zh) | 2018-09-28 |
AU2017216926A1 (en) | 2018-08-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7003045B2 (ja) | 神経変性の治療のための方法及び医薬組成物 | |
Rowinska-Zyrek et al. | Neurodegenerative diseases–understanding their molecular bases and progress in the development of potential treatments | |
US9642823B2 (en) | Methods of treating tinnitus | |
US20050159364A1 (en) | Copper antagonist compounds | |
CN112188890A (zh) | 治疗铁超负荷的组合物和方法 | |
CA2881974A1 (en) | Laquinimod for treatment of cannabinoid receptor type 1 (cb1) mediated disorders | |
IL207683A (en) | Used in benzene-phenanthromidine alkaloids or in their salts for the treatment of tumors, and benzene-phenanthridine alkaloids | |
JP2010535159A (ja) | レオヌリンの使用およびその組成物 | |
JP2014513065A (ja) | (3aR)−1,3a,8−トリメチル−1,2,3,3a,8,8a−ヘキサヒドロピロロ[2,3−b]インドール−5−イルフェニルカルバメートの有効量およびその使用方法 | |
EA037951B1 (ru) | Фенольное соединение и его комбинация с бензодиазепином, конденсированным с 1,4-дигидропиридином, для лечения поражений центральной нервной и сосудистой систем | |
TWI472519B (zh) | 含正-亞丁基苯酞之醫藥組成物用於治療肝損傷及改善肝功能 | |
CA3211939A1 (en) | Gold clusters, compositions, and methods for treatment of depression | |
US20220031719A1 (en) | Antiviral therapeutic drug combinations | |
US20240252461A1 (en) | Compositions and methods for treatment of demyelination | |
Igartúa et al. | Combined Therapy for Alzheimer’s Disease | |
Zhou et al. | Polydopamine (PDA)-Coated Diselenide-Bridged Mesoporous Silica-based Nanoplatform for Neuroprotection by Reducing Oxidative Stress and Targeting Neuroinflammation in Intracerebral Hemorrhage | |
Yang et al. | Polymeric nanoparticles improved Curcumin brain delivery and its therapeutic efficacy against intracerebral hemorrhage |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20200116 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20201118 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20201201 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20210224 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210531 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210824 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20211112 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20211130 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20211228 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7003045 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |